A 72-Year-Old Man With Heavily Pretreated, Relapsed/Refractory Multiple Myeloma

home / case-based-peer-perspectives / a-72-year-old-man-with-heavily-pretreated-relapsed-refractory-multiple-myeloma

Sagar Lonial, MD, FACP, presents a case of a 72-year-old man with heavily pretreated relapsed/refractory multiple myeloma and discusses treatment options for patients with this diagnosis who have failed multiple prior lines of therapy.

72-Year-Old Man with Heavily Pretreated RRMM

EP. 1: 72-Year-Old Man with Heavily Pretreated RRMM

Sagar Lonial, MD, FACP
March 30th 2021

Sagar Lonial, MD, FACP, summarizes the case of a 72-year-old man with heavily pretreated, triple-class relapsed/refractory multiple myeloma (RRMM).

Watch

Treatment Options for Heavily Pretreated RRMM

EP. 2: Treatment Options for Heavily Pretreated RRMM

Sagar Lonial, MD, FACP
March 30th 2021

Sagar Lonial, MD, FACP, reviews and comments on the treatment options for patients with triple-class relapsed/refractory multiple myeloma (RRMM).

Watch

The DREAMM-2 Trial in RRMM

EP. 3: The DREAMM-2 Trial in RRMM

Sagar Lonial, MD, FACP
March 30th 2021

Principal investigator Sagar Lonial, MD, FACP, discusses the DREAMM-2 trial and relapsed/refractory multiple myeloma.

Watch

Role of Belantamab Mafodotin In the Treatment of Heavily Pretreated RRMM

EP. 4: Role of Belantamab Mafodotin In the Treatment of Heavily Pretreated RRMM

Sagar Lonial, MD, FACP
March 30th 2021

An expert in multiple myeloma provides insight on the role of belantamab mafodotin in the treatment of heavily pretreated patients with relapsed/refractory multiple myeloma.

Watch

Current Status and Future Directions in RRMM

EP. 5: Current Status and Future Directions in RRMM

Sagar Lonial, MD, FACP
March 30th 2021

Sagar Lonial, MD, FACP, discusses the management of heavily pretreated relapsed/refractory multiple myeloma and its future.

Watch